Immunic, Inc.
NASDAQ:IMUXBiotechnology
Healthcare
$7.39 -0.28%
-$0.04 today
- Market cap
- $100.83M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
52W Low $5.06High $15.77
Volume 0.39M
Average 0.27M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$103.23M
FY 2025 · Annual
Net Income
-$97.17M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| 2.37M | 3.18M | 4.43M | 10.02M | 15.57M | |
| 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
IMUX Earnings Waterfall · TTM
NASDAQ:IMUX · Revenue to Net Income
Key Ratios
EPS$-5.98
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$104.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-5.98, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 2, 2026 |
How much revenue does IMUX generate?
Immunic, Inc. (IMUX) reported $0.00 of revenue in fiscal 2025.
Is IMUX profitable?
Immunic, Inc. (IMUX) reported -$97.17M of net income.
Continue the stock analysis
Jump to another research area for this company.